Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

MGNX

SELL

MacroGenics, Inc. · Healthcare · United States · $235M · Avg Vol: $5M/d

26
StockRank
Get insider-trade alerts
Q
22
V
32
M
61
P/E (TTM)
ROE
-140.3%
D/E
1.7x
Dividend %

COMPANY DESCRIPTION

MacroGenics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative antibody-based therapeutics for cancer and other serious diseases. The company utilizes proprietary DART and TRIDENT platforms to create novel bispecific antibodies with enhanced therapeutic potential. MacroGenics aims to address unmet medical needs through its pipeline of differentiated immuno-oncology and autoimmune drug candidates.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue150.0M58.7M150.0M149.5M-0.1%157.1M164.4M94.3M-20.6%
EPS-3.37-1.95-0.15-1.07-1.18-1.07
Shares61.7M62.1M62.8M63.3M+2.6%63.6M
Debt34.8M34.0M37.5M36.8M1.8%36.5M
Equity142.0M152.6M116.1M55.6M-26.8%
Op CF-87.0M-78.2M-68.4M-81.0M-70.0M
Inv CF70.7M-80.1M149.3M-114.1M
Fin CF1.7M150.4M1.0M69.5M
Loading 1Y...
PRICE (1Y)+1.0%
3.703.994.284.574.86Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$4.00
RSI (14)
37.2
52W High
$5.08
From 52W High
0.8%

SCORE BREAKDOWN

Quality
22
ROIC
-31.2%23.9
ROE
-140.3%6.3
GP/Assets
-9.9%6.7
Op. Margin
-161.0%15.2
FCF/Assets
3.9%64.5
Piotroski
316.0
Int. Cover
-7.8x25.2
D/E Ratio
1.72x6.9
Current Ratio
1.90x35.9
Value
32
P/E (TTM)
N/A
EV/EBITDA
-2.8x25.0
P/FCF
23.3x46.5
P/B
12.9x8.9
P/S
1.7x71.6
Div Yield
N/A
Momentum
61
52W High %
79%68.5
RS 6M
114%98.3
SMA 50/200
1.61x99.2
EPS Rev 4W
0.0%62.6
EPS Rev 12W
-5.9%19.1
EPS Improve
-32%12.0
Q Growth
N/A

FUNDAMENTALS

Market Cap
$235M
P/E (Forward)
-3.1x
Gross Margin
-16.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MGNX are excluded.

TickerCompanyMkt CapStockRankSignal
MGNXMacroGenics, Inc.(you)$235M26SELL
SABSSAB Biotherapeutics, Inc.$268M27SELL
FATEFate Therapeutics, Inc.$281M26SELL
OBIOOrchestra BioMed Holdings, Inc.$224M22SELL
VNDAVanda Pharmaceuticals Inc.$312M26SELL
ZNTLZentalis Pharmaceuticals, Inc.$308M28SELL
PRLDPrelude Therapeutics Incorporated$305M24SELL
ACOGAlpha Cognition Inc. Common Stock$172M28SELL
ALXOALX Oncology Holdings Inc.$273M31SELL
NRXPNRx Pharmaceuticals, Inc.$161M27SELL

Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%

MacroGenics, Inc. (MGNX) — Stock Score Summary

MacroGenics, Inc. (MGNX) has a MoatMap StockRank of 26/100 based on Quality (22/100), Value (32/100), and Momentum (61/100) factor scores. The current signal is SELL.

MacroGenics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative antibody-based therapeutics for cancer and other serious diseases. The company utilizes proprietary DART and TRIDENT platforms to create novel bispecific antibodies with enhanced therapeutic potential. MacroGenics aims to address unmet medical needs through its pipeline of differentiated immuno-oncology and autoimmune drug candidates.

Key Financial Metrics

Price$4.00
Market Cap$235M
P/E (Forward)-3.06
Price/Book12.93
Return on Equity-140.3%
Return on Invested Capital-31.2%
Debt/Equity1.72x
Gross Margin-16.2%
Operating Margin-161.0%
Revenue Growth57.5%
Free Cash Flow$10M

MacroGenics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is MacroGenics, Inc.’s (MGNX) StockRank?
MoatMap’s StockRank for MacroGenics, Inc. (MGNX) is 26/100, with a Sell signal. It is a composite of Quality (22), Value (32), and Momentum (61) factor ranks across MoatMap’s 20,000+ stock universe.
Does MacroGenics, Inc. have an economic moat?
MacroGenics, Inc. (MGNX) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is MacroGenics, Inc. a buy, hold, or sell?
MoatMap’s current signal for MacroGenics, Inc. (MGNX) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is MacroGenics, Inc. in?
MacroGenics, Inc. (MGNX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).